5
Clinical Trials associated with TQB-3455A Phase I Study of TQB3455 Tablets in Subjects With Advanced Malignancies
This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics of TQB3455 tablets in subjects with advanced malignancies.
TQB3455片在晚期恶性肿瘤患者中的耐受性和药代动力学临床I期试验
[Translation] Phase I clinical trial on the tolerability and pharmacokinetics of TQB3455 tablets in patients with advanced malignant tumors
评价中国晚期恶性肿瘤受试者口服TQB3455片的安全性和耐受性,人体药代动力学特征;确定最大耐受剂量和剂量限制性毒性;评估TQB3455片的初步抗肿瘤疗效。探索TQB3455片的抗肿瘤机制,以及TQB3455片的药物浓度与2-羟基戊二酸(2-HG)的关系。
[Translation] To evaluate the safety and tolerability of oral TQB3455 tablets in Chinese subjects with advanced malignant tumors, and their pharmacokinetic characteristics; to determine the maximum tolerated dose and dose-limiting toxicity; to evaluate the preliminary anti-tumor efficacy of TQB3455 tablets. To explore the anti-tumor mechanism of TQB3455 tablets, and the relationship between the drug concentration of TQB3455 tablets and 2-hydroxyglutaric acid (2-HG).
Phase I Clinical Trial Protocol for Tolerability and Pharmacokinetics of TQB3455 Tablets in Patients With Hematological Malignancies
This study is a clinical trial to evaluate the tolerability and pharmacokinetics of TQB3455 tablets in patients with hematological malignancies. TQB3455 is an isocitrate dehydrogenase 2(IDH2) inhibitor . This project is divided into two stages. The first stage aims to evaluate the safety and tolerability of single or multiple oral administration of TQB3455 tablets in subjects with malignant hematological tumors. The second phase aims to evaluate the efficacy and safety of TQB3455 tablets alone or in combination with azacitidine in subjects with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
100 Clinical Results associated with TQB-3455
100 Translational Medicine associated with TQB-3455
100 Patents (Medical) associated with TQB-3455
100 Deals associated with TQB-3455